병원 밖 전문 심장소생술에서 긴 QT증후군에 의한 Polymorphic Ventricular Tachycardia에 아미오다론이 투여된 1예
Case report : Administration of amiodarone for polymorphic ventricular tachycardia due to long QT syndrome during out-of-hospital advanced cardiac life support
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Torsades de pointes refers to polymorphic ventricular tachycardia (PMVT), which is caused by the suppression of potassium channels owing to genetic and electrolytic abnormalities, resulting in the extension of the QT interval. Symptoms range from spontaneous circulation recovery to fainting and sudden death. Defibrillation, magnesium correction, and the use of lidocaine as an antiarrhythmic agent are recommended as treatments for persistent torsades de pointes. Currently, only amiodarone is available in the ambulance; however, torsades de pointes does not respond efficiently to amiodarone because it suppresses potassium channels and increases the refractory period of the myocardium. Lidocaine, in contrast, reduces the relative refractory period of the myocardium caused by suppressing sodium channels; thus, it inhibits the occurrence of and treats arrhythmia. In cases where PMVT did not respond to defibrillation, the administration of lidocaine showed no difference in survival and discharge rates compared to amiodarone. Thus, ambulances must be equipped with provisions to administer lidocaine.
Abstract
Torsades de pointes refers to polymorphic ventricular tachycardia (PMVT), which is caused by the suppression of potassium channels owing to genetic and electrolytic abnormalities, resulting in the extension of the QT interval. Symptoms range from spontaneous circulation recovery to fainting and sudden death. Defibrillation, magnesium correction, and the use of lidocaine as an antiarrhythmic agent are recommended as treatments for persistent torsades de pointes. Currently, only amiodarone is available in the ambulance; however, torsades de pointes does not respond efficiently to amiodarone because it suppresses potassium channels and increases the refractory period of the myocardium. Lidocaine, in contrast, reduces the relative refractory period of the myocardium caused by suppressing sodium channels; thus, it inhibits the occurrence of and treats arrhythmia. In cases where PMVT did not respond to defibrillation, the administration of lidocaine showed no difference in survival and discharge rates compared to amiodarone. Thus, ambulances must be equipped with provisions to administer lidocaine.
참고문헌 (9)
- Israel CW, "Mechanisms of sudden cardiac death", Indian Heart J, 66(Suppl 1), pp.S10~S17 (2014)[DOI]
- Passman R, "Polymorphic ventricular tachycardia, long QT syndrome, and torsades de pointes", Med Clin North Am, 85(2), pp.321~341 (2001)[DOI]
- Sorajja D, "Optimal antiarrhythmic drug therapy for electrical storm", J Biomed Res, 29(1), pp.20~34 (2015)[DOI]
- Kallergis EM, "Mechanisms, risk factors, and management of acquired long QT syndrome: a comprehensive review", Scientific World J, pp.212178~ (2012)[DOI]
- Dolenska S, "Intraoperative cardiac arrest in acquired long QT syndrome", Br J Anaesth, 102(4), pp.503~505 (2009)[DOI]
- Cohagan B, "Torsade de pointes" (2017)
- Katoh T, "QT prolongation and torsades de pointes during emergency treatment with nifekalant for refractory ventricular tachyarrhythmias:post-hoc analysis from a large-scale multicenter post-marketing survey in Japan", J Arrhythm, 29(5), pp.249~254 (2013)[DOI]
- Hwang SO, "Cardiopulmonary resuscitation and advanced cardiovascular life support", pp.116~285 (2016), Koonja
- Panchal AR, "American Heart Association focused update on advanced cardiovascular life support use of antiarrhythmic drugs during and immediately after cardiac arrest: an update to the American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care", Circulation, 138, pp.e740~e749 (2018)[DOI]